Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against EyePoint, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is EyePoint, Inc. (EYPT) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of EyePoint, Inc. (NASDAQ: EYPT).
On August 17, 2026, EyePoint issued a press release “announc[ing] topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD).” The press release disclosed that change from baseline in best corrected visual acuity versus 2 mg aflibercept (Regeneron Pharmaceuticals’ (REGN) Eylea) was not met in the entire dataset. On this news, EyePoint’s stock price fell $9.88 per share, or 66.98%, to close at $4.87 per share on August 17, 2026. Then, on October 19, 2026, EyePoint announced disappointing topline results from its second Phase 3 pivotal clinical trial, LUCIA, evaluating Duravyu for the treatment of wet AMD. The Company disclosed that Duravyu failed to meet its prespecified primary efficacy endpoint of demonstrating statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to the standard-of-care control, Regeneron’s Eylea (aflibercept). In response to the clinical failure, EyePoint announced significant cost-cutting measures, including the immediate termination of its late-stage wet AMD clinical program and a 53% workforce reduction designed to restructure its operations around separate diabetic macular edema programs. Following this news, EyePoint’s stock price fell $2.55 per share, or 85.28%, to close at $0.44 per share on October 19, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether EyePoint, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether EyePoint, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should EyePoint, Inc. (EYPT) Investors Do?
How Did EyePoint, Inc. (EYPT) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”